Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Rivian Automotive

Investors shouldn't assume that these struggling stocks will rebound anytime soon.

2 Risky Stocks That Could Continue Falling This Year

Novavax's NVAX, +0.85% COVID-19 vaccine candidate played a front-and-center role during this week's debate about how best to update the COVID-19 boosters to better protect against omicron.

Novavax is part of the FDA's COVID-19 booster debate, but its vaccine still hasn't been authorized

NVAX stock is on the cusp of the FDA approval that has long eluded the firm, meaning now is the best time to speculate on Novavax. The post Novavax Stock Is in Prime Position For Speculation appeared first on InvestorPlace.

Novavax Stock Is in Prime Position For Speculation

Novavax prototype vaccine (NVX-CoV2373) demonstrates broad immune responses including against Omicron and other circulating variants Pre-clinical data demonstrated that b oosting with Novavax' Omicron or prototype vaccine induces immune response against Omicron variants, including BA.4/5 Novavax will be ready to supply Omicron-based vaccine this fall in accordance with FDA Advisory Committee recommendation GAITHERSBURG, Md. , June 28, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today participated in the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee's (VRBPAC) meeting which resulted in a 19-2 vote to recommend inclusion of a SARS-CoV-2 Omicron component for COVID-19 booster vaccines in the U.S. beginning this fall.

Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants

What does the future hold for this COVID-19 vaccination stock?

3 Reasons to Buy Novavax and 1 to Sell

Lovesac Company

Pinterest

Root

These innovative businesses can put patient investors on a path to financial independence.

5 Unique Stocks That Can Generate Transformational Wealth

The FDA is expected to authorize a fourth COVID-19 vaccine. Here's how it might impact the pandemic.

What Is Novavax?

EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.

Novavax (NVAX) Up as EMA Recommends COVID Jab for Adolescents

The company's COVID-19 vaccine could soon be available to adolescents in the European Union.

Why Novavax Stock Is Soaring This Week

The EUA in Taiwan allows Novavax to begin fulfilling its commitment to the COVAX Facility GAITHERSBURG, Md. , June 23, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization (EUA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in individuals aged 18 years and over.

Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over

Novavax Inc (NASDAQ: NVAX) shares are trading higher Thursday after the company announced that its COVID-19 vaccine was recommended for an expanded conditional marketing authorization in the European Union for adolescents aged 12 through 17. The European Medicines Agency committee.

Why Novavax Stock Is Up 11% Today

Shares of Novavax Inc. NVAX, +10.16% shot up 9.8% in afternoon trading Thursday, after the biotechnology company said its COVID-19 vaccine Nuvaxovid has been recommended by the Committee for Medicinal Products for Human Use (CHMP) for expanded conditional marketing authorization (CMA) in the European Union for people aged 12 through 17. "This recommendation brings us closer to offering adolescents in the EU the first protein-based COVID-19 vaccine developed using an innovative approach to traditional technology," said Novavax Chief Executive Stanley Erck.

Novavax stock surges after COVID-19 vaccine recommended for expanded CMA in the EU for 12-17 year olds

Upon authorization, Nuvaxovid™ would be the first protein-based option for adolescents aged 12 through 17 in Europe Nuvaxovid™ demonstrated 80% efficacy and was generally well-tolerated in adolescents GAITHERSBURG, Md. , June 23, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) for adolescents aged 12 through 17.

Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

Novavax (NVAX) stock is gaining Thursday on news of a recommendation for the vaccine company's Covid-19 shot for teens in Europe. The post Novavax (NVAX) Stock Gains 7% on EMA Recommendations appeared first on InvestorPlace.

Novavax (NVAX) Stock Gains 7% on EMA Recommendations

Novavax did a few encore presentations of its coronavirus vaccine efficacy and safety data at a conference.

Why Novavax Stock Jumped Today

More than two years into the pandemic, Novavax is up for FDA authorization. Here's what it offers that Pfizer and Moderna can't.

Is There a Role for Novavax to Play in the COVID Pandemic?

Rising interest rates and successes by comeptitors make for a bad combination.

Why Novavax Stock Buckled Today

Novavax's vaccine will likely be approved by the FDA relatively soon, but NVAX stock is still facing many obstacles. The post Novavax Stock Can Rally, But It's Still Facing Many Obstacles appeared first on InvestorPlace.

Novavax Stock Can Rally, But It's Still Facing Many Obstacles

Arriving more than two years into the pandemic, here's what Novavax could bring to the immunity table in the US.

Novavax: Could It Change the COVID Vaccine Game?

Moderna

Novavax and Moderna both are betting on the booster market.

Could This News From Moderna Mean Trouble for Novavax?

The Australian regulatory authority has conditionally approved Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over. The provisional registration was based on data from Novavax's Phase 2 trial conducted.

Novavax' Sees Conditional Approval Of COVID-19 Vaccine Booster In Australia As US FDA Delays Its Decision

In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md. , June 13, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over.

News for Novavax Stock (NVAX)